This study together with the DAPA-HF trial supported the position of SGLT2 inhibitors as part of standard of care for patients with HF and a reduced ejection fraction (EF) with or without DM [19,52,74,75]. The gene discussed is SLC5A2; the disease is diabetes mellitus.